Advertisement

Frontiers of Therapy for Patients With Heart Failure

      Abstract

      This review broadly covers advances in heart failure, which is responsible for significant morbidity, mortality, and cost in the United States. It is a heterogeneous condition, and accurate classification helps ensure appropriate application of evidence-based therapies. Hemodynamics are important in acute heart failure syndromes and may help tailor therapy. Neurohormonal modulation forms the cornerstone of chronic systolic heart failure treatment but does not affect outcomes in diastolic heart failure where management goals emphasize optimization of central volume, blood pressure, and atrial rhythm, as well as the treatment of comorbidities. Frontiers of heart failure therapy range from advances in pharmacology (novel inotropic agents and neurohormonal modulators), to cell biology (nucleic acid-based drugs and cell therapy) to biomedical engineering (devices such as ultrafiltration, biventricular pacemakers, implantable cardiac defibrillators, remote monitoring systems, and left ventricular assist devices), and to health systems (risk stratification and integrated care of comorbidities). The ultimate frontier will be to integrate these data effectively to ensure that patients with heart failure consistently receive the best evidenced-based care possible.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Roger V.L.
        • Go A.S.
        • Lloyd-Jones D.M.
        • et al.
        • American Heart Association Statistics Committee and Stroke Statistics Subcommittee
        Heart disease and stroke statistics—2011 update: a report from the American Heart Association.
        Circulation. 2011; 123: e18-e209
        • Owan T.E.
        • Hodge D.O.
        • Herges R.M.
        • et al.
        Trends in prevalence and outcome of heart failure with preserved ejection fraction.
        N Engl J Med. 2006; 355: 251-259
        • Lindenfeld J.
        • Albert N.M.
        • Boehmer J.P.
        • et al.
        Executive summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline.
        J Card Fail. 2010; 16: 475-539
        • Gheorghiade M.
        • Zannad F.
        • Sopko G.
        • et al.
        Acute heart failure syndromes: current state and framework for future research.
        Circulation. 2005; 112: 3958-3968
        • The Escape Investigators and Study Coordinators
        Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial.
        JAMA. 2005; 294: 1625-1633
        • Abraham W.T.
        • Fonarow G.C.
        • Albert N.M.
        • et al.
        Predictors of in-hospital mortality in patients hospitalized for acute heart failure.
        J Am Coll Cardiol. 2008; 52: 347-356
        • Maisel A.
        • Mueller C.
        • Nowak R.
        • et al.
        Mid-region prohormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
        J Am Coll Cardiol. 2010; 55: 2062-2076
        • Mueller C.
        • Scholer A.
        • Laule-Kilia K.
        • et al.
        Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea.
        N Engl J Med. 2004; 350: 647-654
        • Jentzer J.C.
        • DeWald T.A.
        • Hernandez A.F.
        Combination of loop diuretics with thiazide-type diuretics in heart failure.
        J Am Coll Cardiol. 2010; 56: 1527-1534
        • Felker G.M.
        • Lee K.L.
        • Bull D.A.
        • et al.
        Diuretic strategies in patients with acute decompensated heart failure.
        N Engl J Med. 2011; 364: 797-805
        • Costanzo M.R.
        • Saltzberg M.T.
        • Jessup M.
        • et al.
        Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD.
        J Card Fail. 2010; 16: 277-284
        • McMurray J.J.
        • Ostergren J.
        • Swedberg K.
        • et al.
        Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
        Lancet. 2003; 362: 767-771
        • Zannad F.
        • McMurray J.J.
        • Krum H.
        • et al.
        Eplerenone in patients with systolic heart failure and mild symptoms.
        N Engl J Med. 2011; 364: 11-21
        • Juurlink D.N.
        • Mamdani M.M.
        • Lee D.S.
        • et al.
        Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
        N Engl J Med. 2004; 351: 543-551
        • Krum H.
        • Massie B.
        • Abraham W.T.
        • et al.
        Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.
        Eur J Heart Fail. 2011; 13: 107-114
        • Gu J.
        • Noe A.
        • Chandra P.
        • et al.
        Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).
        J Clin Pharm. 2010; 50: 401-414
        • Cleland J.G.
        • Tendera M.
        • Adamus J.
        • et al.
        The perindopril in elderly people with chronic heart failure (PEP-CHF) study.
        Eur Heart J. 2006; 27: 2338-2345
        • Massie B.M.
        • Carson P.E.
        • McMurray J.J.
        • et al.
        Irbesartan in patients with heart failure and preserved ejection fraction.
        N Engl J Med. 2008; 359: 2456-2467
        • Packer M.
        • Bristow M.R.
        • Cohn J.N.
        • et al.
        The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.
        N Engl J Med. 1996; 334: 1349-1355
        • Cohn J.N.
        • Johnson G.
        • Ziesche S.
        • et al.
        A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
        N Engl J Med. 1991; 325: 303-310
        • Dickstein K.
        • Cohen-Solal A.
        • Filippatos G.
        • et al.
        ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology.
        Eur Heart J. 2008; 29: 2388-2442
        • O'Connor C.M.
        • Starling R.C.
        • Hernandez A.F.
        • et al.
        Effect of nesiritide in patients with acute decompensated heart failure.
        N Engl J Med. 2011; 365: 32-43
        • Rathore S.S.
        • Wang Y.
        • Krumholz H.M.
        Sex-based differences in the effect of digoxin for the treatment of heart failure.
        N Engl J Med. 2002; 347: 1403-1411
        • Ahmed A.
        • Rich M.W.
        • Love T.E.
        • et al.
        Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial.
        Eur Heart J. 2006; 27: 178-186
        • Tacon C.L.
        • McCaffrey J.
        • Delaney A.
        Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials.
        Intensive Care Med. 2012; 38: 359-367
        • Packer M.
        • Carver J.R.
        • Rodeheffer R.J.
        • et al.
        Effect of oral milrinone on mortality in severe chronic heart failure.
        N Engl J Med. 1991; 325: 1468-1475
        • Landoni G.
        • Biondi-Zoccai G.
        • Greco M.
        • et al.
        Effects of levosimendan on mortality and hospitalization.
        Crit Care Med. 2012; 40: 634-646
        • Cleland J.G.
        • Teerlink J.R.
        • Senior R.
        • et al.
        The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.
        Lancet. 2011; 378: 676-683
        • Konstam M.A.
        • Gheorghiade M.
        • Burnett J.C.
        • et al.
        Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial.
        JAMA. 2007; 297: 1319-1331
        • Haeusler K.G.
        • Laufs U.
        • Endres M.
        Chronic heart failure and ischemic stroke.
        Stroke. 2001; 42: 2977-2982
        • Cleland J.G.
        • Findlay I.
        • Jafri S.
        • et al.
        The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure.
        Am Heart J. 2004; 148: 157-164
        • Massie B.M.
        • Collins J.F.
        • Ammon S.E.
        • et al.
        Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial.
        Circulation. 2009; 119: 1616-1624
        • Swedberg K.
        • Komajda M.
        • Bohm M.
        • et al.
        Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study.
        Lancet. 2010; 376: 875-885
        • Borlaug B.A.
        • Paulus W.J.
        Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment.
        Eur Heart J. 2011; 32: 670-679
        • Holzmeister J.
        • Leclercq C.
        Implantable cardioverter defibrillators and cardiac resynchronization therapy.
        Lancet. 2011; 378: 722-730
        • Cleland J.G.
        • Daubert J.C.
        • Erdmann E.
        • et al.
        The effect of cardiac resynchronization on morbidity and mortality in heart failure.
        N Engl J Med. 2005; 352: 1539-1549
        • Moss A.J.
        • Hall W.J.
        • Cannom D.S.
        • et al.
        Cardiac-resynchronization therapy for the prevention of heart-failure events.
        N Engl J Med. 2009; 361: 1329-1338
        • Smith S.A.
        • Abraham W.T.
        Device therapy in advanced heart failure: what to put in and what to turn off.
        Congest Heart Fail. 2011; 17: 220-226
        • The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators
        A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
        N Engl J Med. 1997; 337: 1576-1583
        • Moss A.J.
        • Zareba W.
        • Hall W.J.
        • et al.
        Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
        N Engl J Med. 2002; 346: 877-883
        • Steinbeck G.
        • Andresen D.
        • Seidl K.
        • et al.
        Defibrillator implantation early after myocardial infarction.
        N Engl J Med. 2009; 361: 1427-1436
        • Whellan D.J.
        • Ousdigian K.T.
        • Al-Khatib S.M.
        • et al.
        Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) study.
        J Am Coll Cardiol. 2010; 55: 1803-1810
        • van Veldhuisen D.J.
        • Braunschweig F.
        • Conraads V.
        • et al.
        Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure.
        Circulation. 2011; 124: 1719-1726
        • Abraham W.T.
        • Adamson P.B.
        • Bourge R.C.
        • et al.
        Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial.
        Lancet. 2011; 377: 658-666
        • Bourge R.D.
        • Abraham W.T.
        • Adamson P.B.
        • et al.
        Randomized controlled trial of implantable continuous hemodynamic monitoring in patients with advanced heart failure: the COMPASS study.
        J Am Coll Cardiol. 2008; 51: 1073-1079
        • Rose E.A.
        • Gelijns A.C.
        • Moskowitz A.J.
        • et al.
        Long-term use of a left ventricular assist device for end-stage heart failure.
        N Engl J Med. 2001; 345: 1435-1443
        • Slaughter M.S.
        • Rogers J.G.
        • Milano C.A.
        • et al.
        Advanced heart failure treated with continuous-flow left ventricular assist device.
        N Engl J Med. 2009; 361: 2241-2251
        • Kirklin J.K.
        • Naftel D.C.
        • Kormos R.L.
        • et al.
        Third INTERMACS Annual Report: the evolution of destination therapy in the United States.
        J Heart Lung Transplant. 2011; 30: 115-123
        • Schachinger V.
        • Erbs S.
        • Elsasser A.
        • et al.
        Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction.
        N Engl J Med. 2006; 355: 1210-1221
        • Meyer G.P.
        • Wollert K.C.
        • Lotz J.
        • et al.
        Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow up data from the randomized control trial BOOST (Bone Marrow Transfer to enhance ST-elevation infarct regeneration) trial.
        Circulation. 2006; 113: 1287-1294
        • van Rooij E.
        • Marshall W.S.
        • Olson E.N.
        Toward MicroRNA-based therapeutics for heart disease: the sense in anti-sense.
        Circ Res. 2008; 103: 919-928
        • O'Connor C.M.
        • Whellan D.J.
        • Lee K.L.
        • et al.
        Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial.
        JAMA. 2009; 301: 1439-1450
        • Edelmann F.
        • Gelbrich G.
        • Düngen H.D.
        • et al.
        Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study.
        J Am Coll Cardiol. 2011; 58: 1780-1791
        • Leon M.B.
        • Smith C.R.
        • Mack M.
        • et al.
        Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery.
        N Engl J Med. 2010; 363: 1597-1607
        • Hsu L.F.
        • Jaïs P.
        • Sanders P.
        • et al.
        Catheter ablation for atrial fibrillation in congestive heart failure.
        N Engl J Med. 2004; 351: 2373-2383
        • Jones R.H.
        • Velazquez E.J.
        • Michler R.E.
        • et al.
        Coronary bypass surgery with or without surgical ventricular reconstruction.
        N Engl J Med. 2009; 360: 1705-1717
        • O'Connor C.M.
        • Jiang W.
        • Kuchibhatla M.
        • et al.
        Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial.
        J Am Coll Cardiol. 2010; 56: 692-699
        • Bradley T.D.
        • Logan A.G.
        • Kimoff R.J.
        • et al.
        Continuous positive airway pressure for central sleep apnea and heart failure.
        N Engl J Med. 2005; 353: 2025-2033
        • Teschler H.
        • Cowie M.R.
        • d'Ortho M.P.
        • et al.
        Rationale and design of the SERVE-HF Study: treatment of sleep-disordered breathing with predominant central sleep apnea by adaptive servo ventilation in patients with heart failure.
        Am J Respir Crit Care Med. 2010; 181: A5580
        • Ponikowski P.
        • Javaheri S.
        • Michalkiewicz
        • et al.
        Transvenous phrenic stimulation for the treatment of central sleep apnea in heart failure.
        Eur Heart J. 2012; 33: 889-894

      Related References

        • Weintraub N.L.
        • Collins S.P.
        • Pang P.S.
        • et al.
        Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association.
        Circulation. 2010; 122: 1975-1996
        • Nohria A.
        • Tsang S.W.
        • Fang J.C.
        • et al.
        Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure.
        J Am Coll Cardiol. 2003; 40: 1797-1804
        • Fonarow G.C.
        • Adams K.F.
        • Abraham W.T.
        • et al.
        Risk stratification for in-hospital mortality in acute decompensated heart failure: classification and regression tree analysis.
        JAMA. 2005; 293: 572-580
        • Peacock W.F.
        • DeMarco T.
        • Fonarow G.C.
        • et al.
        Cardiac troponin and outcome in acute heart failure.
        New Engl J Med. 2008; 358: 2117-2126
        • van Kimmenade R.R.
        • Januzzi Jr, J.L.
        • Ellinor P.T.
        • et al.
        Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.
        J Am Coll Cardiol. 2006; 48: 1217-1224
        • Januzzi J.F.
        • Peacocok F.
        • Maisel A.S.
        • et al.
        Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE study.
        J Am Coll Cardiol. 2007; 50: 607-613
        • Bolignano D.
        • Basile G.
        • Parisi P.
        • et al.
        Increased plasma neutrophil gelatinase-associated lipocalin level predicts mortality in elderly patients in chronic heart failure.
        Rejuvenation Res. 2009; 12: 7-14
        • Mueller C.
        • Laule-Kilia K.
        • Schindler C.
        • et al.
        Cost effectiveness of B-type natriuretic peptide in patients with acute dyspnea.
        Ann Int Med. 2006; 166: 1081-1087
        • Januzzi J.L.
        • van Kimmenade R.
        • Lainchbury J.
        • et al.
        NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients.
        Eur Heart J. 2006; 27: 330-337
        • Michtalik H.J.
        • Yeh H.C.
        • Campbell C.Y.
        • et al.
        Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure.
        Am J Cardiol. 2011; 107: 1191-1195
        • Bart B.A.
        • Boyle A.
        • Bank A.J.
        • et al.
        Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial.
        J Am Coll Cardiol. 2005; 46: 2043-2046
        • Costanzo M.R.
        • Guglin M.E.
        • Saltzberg M.T.
        • et al.
        Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure.
        J Am Coll Cardiol. 2007; 49: 675-683
        • The CONSENSUS Trial Study Group
        Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).
        N Engl J Med. 1987; 316: 1429-1435
        • The SOLVD Investigators
        Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
        N Engl J Med. 1991; 325: 293-302
        • Granger C.B.
        • McMurray J.J.
        • Yusuf S.
        • et al.
        Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
        Lancet. 2003; 362: 772-776
        • Pitt B.
        • Zannad F.
        • Remme W.
        • et al.
        The effect of spironolactone on morbidity and mortality in patients with severe heart failure.
        N Engl J Med. 1999; 341: 709-717
        • Pitt B.
        • Remme W.
        • Zannad F.
        • et al.
        Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
        N Engl J Med. 2003; 348: 1309-1321
        • Gheorghiade M.
        • Albaghdadi M.
        • Zannad F.
        • et al.
        Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT).
        Eur J Heart Fail. 2011; 13: 100-106
        • Yusuf S.
        • Pfeffer M.A.
        • Swedberg K.
        • et al.
        Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
        Lancet. 2003; 362: 777-781
        • Desai A.S.
        • Lewis E.F.
        • Li R.
        • et al.
        Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.
        Am Heart J. 2011; 162: 966-972
        • Edelmann F.
        • Schmidt A.G.
        • Gelbrich G.
        • et al.
        Rationale and design of the ‘aldosterone receptor blockade in diastolic heart failure’ trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure.
        Eur J Heart Fail. 2010; 12: 874-882
        • CIBIS-II Investigators
        The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
        Lancet. 1999; 353: 9-13
        • The MERIT-HF Investigators
        Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).
        Lancet. 1999; 353: 2001-2007
        • Esler M.D.
        • Krum H.
        • Sobotka P.A.
        • et al.
        Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.
        Lancet. 2010; 376: 1903-1909
        • Birks E.J.
        • George R.S.
        • Hedger M.
        • et al.
        Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study.
        Circulation. 2011; 123: 381-390
        • Cohn J.N.
        • Johnson G.
        • Ziesche S.
        • et al.
        Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure: Results of a Veterans Administration Cooperative Study.
        N Engl J Med. 1986; 314: 1547-1592
        • Taylor Al
        • Ziesche S.
        • Yancy C.
        • et al.
        Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
        N Engl J Med. 2004; 351: 2049-2057
        • Schwartzenberg S.
        • Redfield M.M.
        • From A.M.
        • et al.
        Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy.
        J Am Coll Cardiol. 2012; 59: 442-451
        • The Digitalis Investigation Group
        The effect of digoxin on mortality and morbidity in patients with heart failure.
        N Engl J Med. 1997; 336: 525-533
        • Pullicino P.
        • Thompson J.L.
        • Barton B.
        • et al.
        Warfarin versus aspirin in patients with reduced cardiac ejection fraction: rationale, objective, and design.
        J Card Fail. 2006; 12: 39-46
        • Guazzi M.
        • Vicenzi M.
        • Arena R.
        • et al.
        Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
        Circulation. 2011; 124: 164-174
        • Hare J.M.
        • Mangal B.
        • Brown J.
        • et al.
        Impact of oxypurinol in patients with symptomatic heart failure: results of the OPT-CHF study.
        J Am Coll Cardiol. 2008; 51: 2301-2309
        • McMurray J.J.
        • Teerlink J.R.
        • Cotter G.
        • et al.
        Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
        JAMA. 2007; 298: 2009-2019
        • Gheorghiade M.
        • Erdmann E.
        • Ferrari R.
        • et al.
        Treatment of acute decompensated heart failure with the soluble guanylate cyclase activator cinaciguat: The COMPOSE program – three randomized, controlled, phase IIb studies.
        J Card Fail. 2011; 17 (971-971)
        • Spragg D.D.
        Optimal left ventricular endocardial pacing sites for cardiac resynchronization therapy in patients with ischemic cardiomyopathy.
        J Am Coll Card. 2010; 56: 774-781
        • Burger H.
        • Schwarz T.
        • Ehrlich W.
        • et al.
        New generation of transvenous left ventricular leads:first experience with implantation of multipolar left ventricular leads.
        Exp Clin Cardiol. 2011; 16: 23-26
        • Khan F.Z.
        • Virdee M.S.
        • Hutchinson J.
        • et al.
        Cardiac resynchronization therapy optimization using noninvasive cardiac output measurement.
        Pacing Clin Electrophysiol. 2011; 34: 1527-1536
        • Bardy G.H.
        • Lee K.L.
        • Mark D.B.
        • et al.
        Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
        N Engl J Med. 2005; 352: 225-237
        • Brachmann J.
        • Bohm M.
        • Rybak K.
        • et al.
        Fluid status monitoring with a wireless network to reduce cardiovascular- related hospitalizations and mortality in heart failure: rationale and design of the OptiLink HF Study (Optimization of Heart Failure Management using OptiVol Fluid Status Monitoring and CareLink).
        Eur J Heart Fail. 2011; 13: 796-804
        • Adamson P.B.
        • Magsieski A.
        • Braunschweig F.
        • et al.
        Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system.
        J Am Coll Cardiol. 2003; 41: 565-571
        • Ritzema J.
        • Troughton R.
        • Melton I.
        • et al.
        Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure.
        Circulation. 2010; 121: 1086-1095
        • Chaudhry S.
        • Mattera J.A.
        • Curtis J.P.
        • et al.
        Telemonitoring in patients with heart failure.
        N Engl J Med. 2010; 363: 2301-2309
        • Koehler F.
        • Winkler S.
        • Scheiber M.
        • et al.
        Telemedical interventional monitoring in heart failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study design.
        Eur J Heart Fail. 2010; 12: 1354-1362
        • Mansour S.
        • Roy D.C.
        • Bouchard V.
        • et al.
        COMPARE-AMI trial: comparison of intracoronary injection of CD133+ bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction: rational and design.
        J Cardiovasc Transl Res. 2010; 3: 153-159
        • Assmus B.
        • Honold J.
        • Schachinger V.
        • et al.
        Transcoronary transplantation of progenitor cells after acute myocardial infarction.
        New Engl J Med. 2006; 355: 1222-1232
        • Janssens S.
        • Dubois C.
        • Bogaert J.
        • et al.
        Autologous bone marrow stem cell transfer in patients with ST-elevation myocardial infarction: a double blind, randomized controlled trial.
        Lancet. 2006; 367: 113-121
        • Lunde K.
        • Solheim S.
        • Aakhus S.
        • et al.
        Intraocoronary injection of mononuclear bone marrow cells in acute myocardial infarction.
        New Engl J Med. 2006; 355: 1199-1209
        • Velazquez E.J.
        • Lee K.L.
        • Deja M.A.
        • et al.
        Coronary-artery bypass surgery in patients with left ventricular dysfunction.
        N Engl J Med. 2011; 364: 1607-1616